Sleep disorders in Parkinson's disease: The contribution of the MPTP non-human primate model

Experimental Neurology

Volumn 219, Issue 2, 2009, Pages 574-582

  Barraud, Quentin ^a   Lambrecq, Virginie ^a   Forni, Claude ^b   McGuire, Steve ^c   Hill, Michael ^c   Bioulac, Bernard ^a   Balzamo, Emmanuel ^b   Bezard, Erwan ^a   Tison, François ^a   Ghorayeb, Imad ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b CNRS   (France)

^c Williams House   (United Kingdom)

Author keywords

Excessive daytime sleepiness; MPTP; Non human primates; Parkinson's disease; REM sleep; Sleep disorders

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DAYTIME SOMNOLENCE; DISEASE MODEL; DOPAMINERGIC ACTIVITY; ELECTROENCEPHALOGRAPHY; FEMALE; HOMEOSTASIS; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; REM SLEEP; RHESUS MONKEY; SLEEP DISORDER; SLEEP WAKING CYCLE; TELEMETRY;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BEHAVIOR, ANIMAL; BIOGENIC MONOAMINES; BRAIN; BRAIN CHEMISTRY; DISEASE MODELS, ANIMAL; ELECTROENCEPHALOGRAPHY; FEMALE; MACACA MULATTA; MPTP POISONING; POLYSOMNOGRAPHY; SLEEP DISORDERS; SLEEP, REM; TIME FACTORS; TYROSINE 3-MONOOXYGENASE; WAKEFULNESS;

EID: 69949103567     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2009.07.019     Document Type: Article

References (39)

1. Abbott R.D., Ross G.W., White L.R., Tanner C.M., Masaki K.H., Nelson J.S., Curb J.D., and Petrovitch H. Excessive daytime sleepiness and subsequent development of Parkinson disease. Neurology 65 (2005) 1442-1446
2. Almirall H., Pigarev I., de la Calzada M.D., Pigareva M., Herrero M.T., and Sagales T. Nocturnal sleep structure and temperature slope in MPTP treated monkeys. J. Neural Transm. 106 (1999) 1125-1134
3. Arnulf I., Konofal E., Merino-Andreu M., Houeto J.L., Mesnage V., Welter M.L., Lacomblez L., Golmard J.L., Derenne J.P., and Agid Y. Parkinson's disease and sleepiness: an integral part of PD. Neurology 58 (2002) 1019-1024
4. Balzamo E., Santucci V., Seri B., Vuillon-Cacciuttolo G., and Bert J. Nonhuman primates: laboratory animals of choice for neurophysiologic studies of sleep. Lab. Anim. Sci. 27 (1977) 879-886
5. Barcia C., De Pablos V., Bautista-Hernandez V., Sanchez-Bahillo A., Fernandez-Barreiro A., Poza M., and Herrero M.T. Measurement of motor disability in MPTP-treated macaques using a telemetry system for estimating circadian motor activity. J. Neurosci. Methods 134 (2004) 59-64
6. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., and Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 20 (1973) 415-455
7. Bezard E., and Gross C.E. Compensatory mechanisms in experimental and human parkinsonism: towards a dynamic approach. Prog. Neurobiol. 55 (1998) 93-116
8. Bezard E., Imbert C., Deloire X., Bioulac B., and Gross C.E. A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey. Brain Res. 766 (1997) 107-112
9. Bezard E., Dovero S., Prunier C., Ravenscroft P., Chalon S., Guilloteau D., Crossman A.R., Bioulac B., Brotchie J.M., and Gross C.E. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J. Neurosci. 21 (2001) 6853-6861
10. Bliwise D.L., Willians M.L., Irbe D., Ansari F.P., and Rye D.B. Inter-rater reliability for identification of REM sleep in Parkinson's disease. Sleep 23 (2000) 671-676
11. Boulet S., Mounayar S., Poupard A., Bertrand A., Jan C., Pessiglione M., Hirsch E.C., Feuerstein C., Francois C., Feger J., Savasta M., and Tremblay L. Behavioral recovery in MPTP-treated monkeys: neurochemical mechanisms studied by intrastriatal microdialysis. J. Neurosci. 28 (2008) 9575-9584
12. Braak H., Del Tredici K., Rub U., de Vos R.A., Jansen Steur E.N., and Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24 (2003) 197-211
13. Chaumette T., Lebouvier T., Aubert P., Lardeux B., Qin C., Li Q., Accary D., Bezard E., Bruley des Varannes S., Derkinderen P., and Neunlist M. Neurochemical plasticity in the enteric nervous system of a primate animal model of experimental Parkinsonism. Neurogastroenterol. Motil. 21 (2009) 215-222
14. Daley, J.T., Turner, R.S., Freeman, A., Bliwise, D.L., and Rye, D.B., 2006. Prolonged assessment of sleep and daytime sleepiness in unrestrained Macaca mulatta.
15. Dauer W., and Przedborski S. Parkinson's disease: mechanisms and models. Neuron 39 (2003) 889-909
16. Decamp E., and Schneider J.S. Attention and executive function deficits in chronic low-dose MPTP-treated non-human primates. Eur. J. Neurosci. 20 (2004) 1371-1378
17. Dzirasa K., Ribeiro S., Costa R., Santos L.M., Lin S.C., Grosmark A., Sotnikova T.D., Gainetdinov R.R., Caron M.G., and Nicolelis M.A. Dopaminergic control of sleep-wake states. J. Neurosci. 26 (2006) 10577-10589
18. Forno L.S., Langston J.W., DeLanney L.E., Irwin I., and Ricaurte G.A. Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys. Ann. Neurol. 20 (1986) 449-455
19. Ghorayeb I., Fernagut P.O., Aubert I., Bezard E., Poewe W., Wenning G.K., and Tison F. Toward a primate model of L-dopa-unresponsive parkinsonism mimicking striatonigral degeneration. Mov. Disord. 15 (2000) 531-536
20. Ghorayeb I., Loundou A., Auquier P., Dauvilliers Y., Bioulac B., and Tison F. A nationwide survey of excessive daytime sleepiness in Parkinson's disease in France. Mov. Disord. 22 (2007) 1567-1572
21. Happe S., Baier P.C., Helmschmied K., Meller J., Tatsch K., and Paulus W. Association of daytime sleepiness with nigrostriatal dopaminergic degeneration in early Parkinson's disease. J. Neurol. 254 (2007) 1037-1043
22. Hsieh K.C., Robinson E.L., and Fuller C.A. Sleep architecture in unrestrained rhesus monkeys (Macaca mulatta) synchronized to 24-hour light-dark cycles. Sleep 31 (2008) 1239-1250
23. Imbert C., Bezard E., Guitraud S., Boraud T., and Gross C.E. Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the Macaque monkey. J. Neurosci. Methods 96 (2000) 71-76
24. Kripke D.F., Reite M.L., Pegram G.V., Stephens L.M., and Lewis O.F. Clinical and laboratory notes. Nocturnal sleep in rhesus monkeys. Electroencephalogr. Clin. Neurophysiol. 24 (1968) 582-586
25. Langston J.W., Forno L.S., Rebert C.S., and Irwin I. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey. Brain Res. 292 (1984) 390-394
26. Lima M.M., Andersen M.L., Reksidler A.B., Vital M.A., and Tufik S. The role of the substantia nigra pars compacta in regulating sleep patterns in rats. PLoS ONE 2 (2007) e513
27. Meissner W., Ravenscroft P., Reese R., Harnack D., Morgenstern R., Kupsch A., Klitgaard H., Bioulac B., Gross C.E., Bezard E., and Boraud T. Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine. Neurobiol. Dis. 22 (2006) 586-598
28. Mounayar S., Boulet S., Tande D., Jan C., Pessiglione M., Hirsch E.C., Feger J., Savasta M., Francois C., and Tremblay L. A new model to study compensatory mechanisms in MPTP-treated monkeys exhibiting recovery. Brain 130 (2007) 2898-2914
29. Oiwa Y., Eberling J.L., Nagy D., Pivirotto P., Emborg M.E., and Bankiewicz K.S. Overlesioned hemiparkinsonian non human primate model: correlation between clinical, neurochemical and histochemical changes. Front. Biosci. 8 (2003) a155-166
30. Ozaki N., Nakahara D., Kaneda N., Kiuchi K., Okada T., Kasahara Y., and Nagatsu T. Acute effects of 1-methyl-4-phenylpyridinium ion (MPP+) on dopamine and serotonin metabolism in rat striatum as assayed in vivo by a micro-dialysis technique. J. Neural Transm. 70 (1987) 241-250
31. Postuma R.B., and Montplaisir J. Potential early markers of Parkinson's disease in idiopathic rapid-eye-movement sleep behaviour disorder. Lancet Neurol. 5 (2006) 552-553
32. Pungor K., Papp M., Kekesi K., and Juhasz G. A novel effect of MPTP: the selective suppression of paradoxical sleep in cats. Brain Res. 525 (1990) 310-314
33. Rechtschaffen A., and Kales A. A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects (1968), Public Health Service, US Government Printing Office, Washington DC
34. Rollema H., Damsma G., Horn A.S., De Vries J.B., and Westerink B.H. Brain dialysis in conscious rats reveals an instantaneous massive release of striatal dopamine in response to MPP+. Eur. J. Pharmacol. 126 (1986) 345-346
35. Rye D.B. The two faces of Eve: dopamine's modulation of wakefulness and sleep. Neurology 63 (2004) S2-7
36. Schenck C.H., Bundlie S.R., and Mahowald M.W. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 46 (1996) 388-393
37. Tandberg E., Larsen J.P., and Karlsen K. A community-based study of sleep disorders in patients with Parkinson's disease. Mov. Disord. 13 (1998) 895-899
38. van Hilten J.J., Weggeman M., van der Velde E.A., Kerkhof G.A., van Dijk J.G., and Roos R.A. Sleep, excessive daytime sleepiness and fatigue in Parkinson's disease. J. Neural Transm. Parkinson¢s Dis. Dement. Sect. 5 (1993) 235-244
39. Zigmond M.J., Abercrombie E.D., Berger T.W., Grace A.A., and Stricker E.M. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci. 13 (1990) 290-296